Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration

W Sauerbrei, SE Taube, LM McShane… - JNCI: Journal of the …, 2018 - academic.oup.com
Abstract The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
were developed to address widespread deficiencies in the reporting of such studies. The …

HER2 in breast cancer: a review and update

U Krishnamurti, JF Silverman - Advances in anatomic pathology, 2014 - journals.lww.com
HER2 (human epidermal growth factor receptor 2) receptor is a membrane tyrosine kinase
and when activated affects cell proliferation and survival. The HER2 oncogene is located on …

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

DG Altman, LM McShane, W Sauerbrei, SE Taube - BMC medicine, 2012 - Springer
Abstract Background The Reporting Recommendations for Tumor Marker Prognostic
Studies (REMARK) checklist consists of 20 items to report for published tumor marker …

Magnetoferritin nanoparticles for targeting and visualizing tumour tissues

K Fan, C Cao, Y Pan, D Lu, D Yang, J Feng… - Nature …, 2012 - nature.com
Engineered nanoparticles have been used to provide diagnostic 1, 2, 3, therapeutic 4, 5 and
prognostic information 6, 7 about the status of disease. Nanoparticles developed for these …

Tissue microarrays for high-throughput molecular profiling of tumor specimens

J Kononen, L Bubendorf, A Kallionimeni, M Bärlund… - Nature medicine, 1998 - nature.com
Many genes and signalling pathways controlling cell proliferation, death and differentiation,
as well as genomic integrity, are involved in cancer development. New techniques, such as …

The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine

JS Ross, EA Slodkowska, WF Symmans… - The …, 2009 - academic.oup.com
Learning Objectives Contrast the current strengths and limitations of the three main slide-
based techniques (IHC, FISH, and CISH) currently in clinical use for testing breast cancer …

The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

JS Ross, JA Fletcher - Stem cells, 1998 - academic.oup.com
The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with
extensive homology to the epidermal growth factor receptor. HER-2/neu has been widely …

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian …

CM Sturgeon, MJ Duffy, UH Stenman, H Lilja… - 2008 - academic.oup.com
Abstract Background: Updated National Academy of Clinical Biochemistry (NACB)
Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been …

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

MA Owens, BC Horten, MM Da Silva - Clinical breast cancer, 2004 - Elsevier
To analyze HER2 amplification in a large cohort of diagnostic breast cancer specimens,
fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were performed …

The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

JS Ross, JA Fletcher, GP Linette, J Stec, E Clark… - The …, 2003 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Define
the historical background and biological basis of the discovery of the HER-2/neu gene and …